International Journal of Colorectal Disease

, Volume 29, Issue 6, pp 673–680 | Cite as

Can hyperthermic intraperitoneal chemotherapy efficiency be improved by blocking the DNA repair factor COP9 signalosome?

  • Mathilde Feist
  • Xiaohua Huang
  • Joachim M. Müller
  • Beate Rau
  • Wolfgang DubielEmail author
Original Article



A frequently used chemotherapeutic agent in hyperthermic intraperitoneal chemotherapy (HIPEC) is mitomycin C (MMC) which induces DNA damage and apoptosis in tumor cells. In addition, MMC activates DNA damage response (DDR) leading to repair mechanisms counteracting the effect of chemotherapy. COP9 signalosome (CSN) positively influences the DDR pathway by its intrinsic deneddylating and associated kinase activities. In an in vitro HIPEC model, we studied the impact of curcumin, an inhibitor of CSN-associated kinases, and of the microRNA (miRNA) let-7a-1, an inhibitor of CSN subunit expression, on the MMC-induced apoptosis in human HT29 colon cancer cells.


Cells were incubated at 37 °C and indicated concentrations of MMC in a medium preheated to 42 °C as under HIPEC conditions for 1 or 4 h. HT29 cells were cotreated with 50 μM curcumin or transfected with let-7a-1 miRNA mimic. After incubation, cells were analyzed by Western blotting, densitometry, and caspase-3 ELISA.


An increase of CSN subunits in response to MMC treatment was detected. Apoptosis was only measured after 4 h with 50 μM MMC. MMC-induced apoptosis was elevated by cotreatment with curcumin. Transfection of HT29 cells with let-7a-1 reduced the expression of tested CSN subunits associated with the accumulation of the pro-apoptotic factors p27 and p53.


In response to MMC treatment, the CSN is elevated as a regulator of DDR retarding apoptosis in tumor cells. The therapeutic effect of HIPEC can be increased by inhibiting CSN-associated kinases via curcumin or by blocking CSN expression with let-7a-1 miRNA.


HIPEC COP9 signalosome Chemotherapy DNA repair Apoptosis 



This work was supported by funding from the Charité-Universitätsmedizin Berlin.


The authors declare no disclosures.


  1. 1.
    Weber T, Roitman M, Link KH (2012) Current status of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer. Clin Colorectal Cancer 11:167–176PubMedCrossRefGoogle Scholar
  2. 2.
    Turaga K, Levine E, Barone R et al. (2013) Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States. Ann Surg OncolGoogle Scholar
  3. 3.
    Tsilimparis N, Bockelmann C, Raue W et al (2013) Quality of life in patients after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is it worth the risk? Ann Surg Oncol 20:226–232PubMedCrossRefGoogle Scholar
  4. 4.
    Raue W, Kilian M, Braumann C et al (2010) Multimodal approach for treatment of peritoneal surface malignancies in a tumour-bearing rat model. Int J Colorectal Dis 25:245–250PubMedCrossRefGoogle Scholar
  5. 5.
    Spiliotis JD (2010) Peritoneal carcinomatosis cytoreductive surgery and HIPEC: a ray of hope for cure. Hepatogastroenterology 57:1173–1177PubMedGoogle Scholar
  6. 6.
    Bouquet W, Boterberg T, Ceelen W et al (2009) In vitro cytotoxicity of paclitaxel/beta-cyclodextrin complexes for HIPEC. Int J Pharm 367:148–154PubMedCrossRefGoogle Scholar
  7. 7.
    Yan TD, Deraco M, Baratti D et al (2009) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 27:6237–6242PubMedCrossRefGoogle Scholar
  8. 8.
    Glehen O, Kwiatkowski F, Sugarbaker PH et al (2004) Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 22:3284–3292PubMedCrossRefGoogle Scholar
  9. 9.
    Sugarbaker PH (2007) Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy. Int J Hyperthermia 23:431–442PubMedCrossRefGoogle Scholar
  10. 10.
    Tomasz M, Palom Y (1997) The mitomycin bioreductive antitumor agents: cross-linking and alkylation of DNA as the molecular basis of their activity. Pharmacol Ther 76:73–87PubMedCrossRefGoogle Scholar
  11. 11.
    Hannss R, Dubiel W (2011) COP9 signalosome function in the DDR. FEBS Lett 585:2845–2852PubMedCrossRefGoogle Scholar
  12. 12.
    Deng XW, Dubiel W, Wei N et al (2000) Unified nomenclature for the COP9 signalosome and its subunits: an essential regulator of development. Trends Genet 16:202–203PubMedCrossRefGoogle Scholar
  13. 13.
    Schwechheimer C, Isono E (2010) The COP9 signalosome and its role in plant development. Eur J Cell Biol 89:157–162PubMedCrossRefGoogle Scholar
  14. 14.
    Braus GH, Irniger S, Bayram O (2010) Fungal development and the COP9 signalosome. Curr Opin Microbiol 13:672–676PubMedCrossRefGoogle Scholar
  15. 15.
    Kato JY, Yoneda-Kato N (2009) Mammalian COP9 signalosome. Genes Cells 14:1209–1225PubMedCrossRefGoogle Scholar
  16. 16.
    Schmaler T, Dubiel W 2010 Control of deneddylation by the COP9 signalosome. Vol. 54. Austin, New York: Landes Bioscience and Springer Science + Business MediaGoogle Scholar
  17. 17.
    Seeger M, Kraft R, Ferrell K et al (1998) A novel protein complex involved in signal transduction possessing similarities to 26S proteasome subunits. Faseb J 12:469–478PubMedGoogle Scholar
  18. 18.
    Cope GA, Suh GS, Aravind L et al (2002) Role of predicted metalloprotease motif of Jab1/Csn5 in cleavage of Nedd8 from Cul1. Science 298:608–611PubMedCrossRefGoogle Scholar
  19. 19.
    Uhle S, Medalia O, Waldron R et al (2003) Protein kinase CK2 and protein kinase D are associated with the COP9 signalosome. Embo J 22:1302–1312PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Sun L, Shi L, Wang F et al (2010) Substrate phosphorylation and feedback regulation in JFK-promoted p53 destabilization. J Biol Chem 286:4226–4235PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Huang X, Wagner E, Dumdey R et al (2006) Phosphorylation by COP9 signalosome-associated CK2 promotes degradation of p27 during the G1 cell cycle phase. Israel J Chem 46:231–238CrossRefGoogle Scholar
  22. 22.
    Bech-Otschir D, Kraft R, Huang X et al (2001) COP9 signalosome-specific phosphorylation targets p53 to degradation by the ubiquitin system. Embo J 20:1630–1639PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Fullbeck M, Huang X, Dumdey R et al (2005) Novel curcumin- and emodin-related compounds identified by in silico 2D/3D conformer screening induce apoptosis in tumor cells. BMC Cancer 5:97PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Braumann C, Tangermann J, Jacobi CA et al (2008) Novel anti-angiogenic compounds for application in tumor therapy—COP9 signalosome-associated kinases as possible targets. Mini Rev Med Chem 8:421–428PubMedCrossRefGoogle Scholar
  25. 25.
    Leppert U, Henke W, Huang X et al (2011) Post-transcriptional fine-tuning of COP9 signalosome subunit biosynthesis is regulated by the c-Myc/Lin28B/let-7 pathway. J Mol Biol 409:710–721PubMedCrossRefGoogle Scholar
  26. 26.
    Petroski MD, Deshaies RJ (2005) Function and regulation of cullin-RING ubiquitin ligases. Nat Rev Mol Cell Biol 6:9–20PubMedCrossRefGoogle Scholar
  27. 27.
    Saha A, Deshaies RJ (2008) Multimodal activation of the ubiquitin ligase SCF by Nedd8 conjugation. Mol Cell 32:21–31PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Deshaies RJ, Joazeiro CA (2009) RING domain E3 ubiquitin ligases. Annu Rev Biochem 78:399–434PubMedCrossRefGoogle Scholar
  29. 29.
    Schmidt MW, McQuary PR, Wee S et al (2009) F-box-directed CRL complex assembly and regulation by the CSN and CAND1. Mol Cell 35:586–597PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Zemla A, Thomas Y, Kedziora S et al (2013) CSN- and CAND1-dependent remodelling of the budding yeast SCF complex. Nat Commun 4:1641PubMedCrossRefGoogle Scholar
  31. 31.
    Groisman R, Polanowska J, Kuraoka I et al (2003) The ubiquitin ligase activity in the DDB2 and CSA complexes is differentially regulated by the COP9 signalosome in response to DNA damage. Cell 113:357–367PubMedCrossRefGoogle Scholar
  32. 32.
    Dohmann EM, Levesque MP, De Veylder L et al (2008) The Arabidopsis COP9 signalosome is essential for G2 phase progression and genomic stability. Development 135:2013–2022PubMedCrossRefGoogle Scholar
  33. 33.
    Beli P, Lukashchuk N, Wagner SA et al (2012) Proteomic investigations reveal a role for RNA processing factor THRAP3 in the DNA damage response. Mol Cell 46:212–225PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    Matsuoka S, Ballif BA, Smogorzewska A et al (2007) ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 316:1160–1166PubMedCrossRefGoogle Scholar
  35. 35.
    González-Moreno S, González-Bayón LA, Ortega-Pérez G (2010) Hyperthermic intraperitoneal chemotherapy: rationale and technique. World J Gastrointest Oncol 2:68–75PubMedCentralPubMedCrossRefGoogle Scholar
  36. 36.
    Weston CR, Davis RJ (2007) The JNK signal transduction pathway. Curr Opin Cell Biol 19:142–149PubMedCrossRefGoogle Scholar
  37. 37.
    Aggarwal BB, Sung B (2009) Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci 30:85–94PubMedCrossRefGoogle Scholar
  38. 38.
    Sampson VB, Rong NH, Han J et al (2007) MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res 67:9762–9770PubMedCrossRefGoogle Scholar
  39. 39.
    Francescutti V, Rivera L, Seshadri M et al (2013) The benefit of intraperitoneal chemotherapy for the treatment of colorectal carcinomatosis. Oncol Rep 30:35–42PubMedCentralPubMedGoogle Scholar
  40. 40.
    Pelz JO, Vetterlein M, Grimmig T et al (2013) Hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis: role of heat shock proteins and dissecting effects of hyperthermia. Ann Surg Oncol 20:1105–1113PubMedCrossRefGoogle Scholar
  41. 41.
    Fischer ES, Scrima A, Bohm K et al (2011) The molecular basis of CRL4DDB2/CSA ubiquitin ligase architecture, targeting, and activation. Cell 147:1024–1039PubMedCrossRefGoogle Scholar
  42. 42.
    Echalier A, Pan Y, Birol M et al (2013) Insights into the regulation of the human COP9 signalosome catalytic subunit, CSN5/Jab1. Proc Natl Acad Sci U S A 110:1273–1278PubMedCentralPubMedCrossRefGoogle Scholar
  43. 43.
    Higa LA, Mihaylov IS, Banks DP et al (2003) Radiation-mediated proteolysis of CDT1 by CUL4-ROC1 and CSN complexes constitutes a new checkpoint. Nat Cell Biol 5:1008–1015PubMedCrossRefGoogle Scholar
  44. 44.
    Sertic S, Evolvi C, Tumini E, et al. (2013) Non-canonical CRL4A/4B(CDT2) interacts with RAD18 to modulate post replication repair and cell survival. PLoS One 8:e60000Google Scholar
  45. 45.
    Hoshino I, Matsubara H (2013) MicroRNAs in cancer diagnosis and therapy: from bench to bedside. Surg Today 43:467–478Google Scholar
  46. 46.
    Nana-Sinkam SP, Croce CM (2013) Clinical applications for microRNAs in cancer. Clin Pharmacol Ther 93:98–104PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Mathilde Feist
    • 1
  • Xiaohua Huang
    • 1
  • Joachim M. Müller
    • 2
  • Beate Rau
    • 2
  • Wolfgang Dubiel
    • 1
    Email author
  1. 1.Division of Molecular Biology, Department of General, Visceral, Vascular and Thoracic SurgeryCharité-Universitätsmedizin BerlinBerlinGermany
  2. 2.Department of General, Visceral, Vascular and Thoracic SurgeryCharité-Universitätsmedizin BerlinBerlinGermany

Personalised recommendations